Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.

Cara A. Rosenbaum,Leonor A Stephens,Vishal Kukreti,Jeffrey A. Zonder,Craig E. Cole,Todd M. Zimmerman,Donna E. Reece,Jesus G. Berdeja,Erica Severson,Andrea Revethis,Brittany Wolfe,Kathryn McDonnell,Jennifer Nam,Kent A. Griffith,Andrzej Jakubowiak

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone (KPd) in patients (Pts) with relapsed/refractory multiple myeloma (RRMM): A Multiple Myeloma Research Consortium multicenter study.

2016

Cara A. Rosenbaum
Leonor A Stephens
Vishal Kukreti
Jeffrey A. Zonder
Craig E. Cole
Todd M. Zimmerman
Donna E. Reece
Jesus G. Berdeja
Erica Severson
Andrea Revethis
Brittany Wolfe
Kathryn McDonnell
Jennifer Nam
Kent A. Griffith
Andrzej Jakubowiak

8007Background: The combination of carfilzomib (CFZ), pomalidomide (POM) and dexamethasone (DEX) showed very promising activity in advanced RRMM. In this phase 1/2 study, KPd was evaluated in less-...

Keywords:

Oncology
Dexamethasone
Pomalidomide
Refractory Multiple Myeloma
Pathology
Carfilzomib
Medicine
Multiple myeloma
Internal medicine
relapsed refractory
multicenter study
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations